BioNJ Manufacturing Briefing 2022

Newark, NJ. September 9, 2022: Delphine Diagnostics’ CEO, Andy Bala, attended Manufacturing Briefing 2022 at NJIT and NJ Innovation Institute, both in Newark, NJ. The event was in-person and organized by BioNJ. BioNJ, McKinsey, a few big pharma firms, and FDA came together to share forward-looking updates relevant to the BioPharma manufacturing space for the next two years. The highlights of the event were presentations, Q&A sessions, networking, and a walkthrough of McKinsey’s Digital Capability Center- touted as a Digital AI/ML Capability Center – Demonstrated by McKinsey’s team, which was meant for Scientists/Technicians in manufacturing space to learn/hone the needed skills. Andy Bala said, “It was a wonderful event to hear about the manufacturing strategies for the near future and how we can adapt and accelerate along the way. It was also a great networking event, and we found prospective partners to manufacture our Sepsis Diagnostic Kit locally here in New Jersey. “ More info about BioNJ and its upcoming events can be found at the following link: https://bionj.org/

————————-

DELPHINE DIAGNOSTICS INC BECAME AN INAUGURAL MEMBER OF THE SEPSIS INNOVATION COLLABORATIVE (SIC)

Great news from the Delphine team! Delphine Diagnostics accepted an invitation to join as an inaugural member of the Sepsis Innovation Collaborative (SIC) led by Sepsis Alliance. Delphine’s CEO, Andy Bala, stated that “we look forward to serving by volunteering our time and talents to provide the latest research and marketable products to clinicians and patients. Delphine’s research and development team is committed to providing high-quality data for research and analytical purposes produced by our daily operations.” More info about SIC: https://lnkd.in/g5Gnipjz Sepsis Innovation Collaborative (SIC) is a multi-stakeholder public/private collaborative launched by Sepsis Alliance that brings academic, clinical, industry, patient advocacy, reimbursement, research, and other stakeholders together with the common mission to address the challenges and unmet needs related to infection management and sepsis prevention, detection, treatment, and survivor support. SIC members: – Facilitate public-private communication with U.S. government agencies on opportunities to accelerate innovation – Develop a common sepsis lexicon – Connect longitudinal sepsis patient and survivor data – Improve equity across the infection management/sepsis continuum in underserved communities and vulnerable populations – Accelerate the time-to-market of novel products and services – Address the long-term healthcare challenges of sepsis survivors

#sepsisawareness #collaboration #delphinedx #healthcare #opportunities #innovation

————–

BIONJ’S TWELFTH ANNUAL BIOPARTNERING CONFERENCE

New Jersey, May 9, 2022: Biotech Industry Association in New Jersey ‘BioNJ’ had organized a BioPartnering networking event on May 9, 2022, in Liberty Park, New Jersey, across from New York City. Johnson & Johnson and JP Morgan chase were major sponsors of the event. Andy Bala of Delphine Diagnostics was invited as a guest of BioNJ and developed a few contacts to further Delphine’s business interests. Click here for more info!

——————

THE STATE OF THE STATE OF MANUFACTURING

Trenton, NJ, May 5, 2022: Delphine Diagnostics Inc’s CEO, Andy Bala, attended the State of the State of Manufacturing. The event took place in Patriots Theater at the Trenton War Memorial. Andy Bala said, “It was a great initiative to start a dialogue with New Jersey State Legislators and share feedback regarding challenges faced by startup and small to medium-sized manufacturers based out of New Jersey. Absolutely it was a value-add event with two clear goals, driving more diversity in participation and more effective engagement with State Lawmakers in the future at Trenton, NJ.” More than 400 New Jersey manufacturers gathered in person in the Town Hall style gathering to discuss the challenges and concerns of NJ Manufacturers. More information about NJMEP is below.

Richard Weber of Ethos Biosciences (left), Peter Russo of NJMEP, and Andy Bala- Delphine Diagnostics (right)

ABOUT NJMEP

New Jersey Manufacturing Extension Program, Inc. (NJMEP) is a not-for-profit company that works with New Jersey’s small to mid-sized manufacturers to help them become more efficient, profitable, and globally competitive.

A Meaningful Collaboration Between Rutgers Business School and Delphine Diagnostics Inc

March 17, 2022

In the pictures: Delphine’s CEO, Andy (Andiappan) Bala, is working with the Rutgers Business School students. The students are serving in an excelling program and gaining real work-life experiences. The rewards are countless when investing in young minds, collaboration, expertise, and access.

Delphine Diagnostics Inc. Participated in the BAJ Accelerator Program

New York, January 2022: Delphine Diagnostics Team joined the NYC-based BAJ Accelerator Program as of January 2022 Cohort #7. The program helped build new connections and offered valuable resources to startups. The Delphine Diagnostics Team received compliments, constructive criticism, and training and coaching through the BAJ Accelerator Program. According to Andy Bala, CEO of Delphine, “All in all, it was a great program, and we learned so much about startup business. We are very appreciative of all the support and resources we received.” More information about the program is below. (Source: https://www.bajaccelerator.com)

Picture from the BAJ Accelerator Gallery

ABOUT THE BAJ ACCELERATOR

BAJ Accelerator is a growth stage accelerator and is for startups at the Seed to Series A+ levels. The program includes significant networking opportunities with investors, targeted coaching, customer interviews, collaboration sessions and full-day training sessions from top-level executives from around the globe. Topics span an impressive range including technology, legal, finance, sales, marketing, leadership, storytelling and exponential thinking. The key knowledge goal of BAJ Accelerator is to support founders in enabling their startups to become investable. BAJ Accelerator was made possible by a collaboration among three organizations: Baltic American Chamber of Commerce, Orion Worldwide Innovations LLC and Jacobs Technion-Cornell Institute at Cornell Tech. Jacobs Technion-Cornell Institute was established jointly by Cornell University and the Technion-Israel Institute of Technology.

We are so thrilled that Delphine Diagnostics’ leadership team participated in the Puerto Rico Biosciences Emerging Companies Network. Our presentation received significant attention, and we made new connections on the island. Special thanks to A4G, The Puerto Rico Economic Development Alliance, for organizing such events, bringing us together, and building platforms. Thanks to Andy Bala, Ethlyn Haseth – Wolstenholme, Laura M Ferguson, PhD, Sreyashi Samaddar PhD! #delphinedx #delphinediagnostics #healthcare #development #opportunity #growth #team #connections #network #innovation —

The Puerto Rico Economic Development Alliance hosted a round table with 12 healthcare start-ups where among other topics, the history, attributes, and feasibility of the island were shared to facilitate their entrance into the Puerto Rican market. The objective was to get to know the Companies that have chosen Puerto Rico or are exploring this market for their development & growth. “The Alliance wanted to provide the appropriate forum to discuss their vision of development. As well as the areas of opportunity that the island has to attract and retain these industries that see PR as an option to develop and establish their operations”, said Rodrigo Masses. During the discussion, which was hosted at the Verdanza Hotel in Isla Verde and organized by the Alliance, which is an organization comprised of leaders of the private sector with the objective of providing a platform that serves as a guide to the economic development of the island. It was stated that the goal of the meeting was to meet and guide the Companies that are considering or have chosen Puerto Rico for their growth, their projects and challenges, and what motivates them to select the island. Among points discussed, the Companies agreed that establishing themselves in PR represents an added value because the island has exceptional talent trained and experienced by the pharmaceutical industry as well as the ideal ecosystem for the development of the industry. Also noted were the challenges to continue developing the industry include energy, changes to the US tax laws, the pandemic, R&D infrastructure, and access to investment capital. Continue reading …

Tagged Delphine Diagnostics

2022